Repligen (RGEN)
(Real Time Quote from BATS)
$143.50 USD
-1.48 (-1.02%)
Updated Nov 7, 2025 09:36 AM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Repligen has a PEG ratio of 2.75 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.71.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RGEN 143.50 -1.48(-1.02%)
Will RGEN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RGEN based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for RGEN
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Here's Why Repligen (RGEN) is a Strong Growth Stock
RGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RGEN
Is RGEN gaining bearish strength? New Downtrend shows up after sinking 0.59%
Non-ADX 1,2,3,4 Bullish appears for RGEN after 0.74% move
Is RGEN preparing to trend higher? Stochastic Buy Signal shows up after slipping 2.16%
NR7 appears for RGEN after 0.74% move
H.C. Wainwright Remains a Buy on Repligen (RGEN)